Ireland's HPRA Guidance: GDP Quality Systems, GXP Regulatory Advice, and Active Substance Registration Changes
- Sharan Murugan
- 6 hours ago
- 3 min read
The Health Products Regulatory Authority (HPRA) has released updated guidance documents to strengthen pharmaceutical quality systems, regulatory compliance, and operational oversight across Ireland’s healthcare sector. The updated guidance documents include:
Together, these documents highlight the increasing regulatory focus on quality risk management, inspection readiness, supply chain oversight, documentation control, and proactive regulatory engagement throughout pharmaceutical operations.
The updated guidance, published by the HPRA on 20 May 2026, provides detailed expectations on the minimum requirements for a compliant GDP quality management system for wholesale distributors.
The guidance explains that a quality management system should consist of controlled written procedures, forms, records, and operational processes that ensure medicinal products are consistently handled, stored, transported, and distributed according to GDP principles. Companies are expected to maintain documented systems that clearly define operational responsibilities and standardised procedures across all distribution activities.
The guidance also explains that HPRA inspections are performed using a risk-based approach. Inspection frequency may vary depending on factors such as compliance history, operational changes, and previous inspection findings. Companies are also required to submit annual compliance assessment reports to support ongoing regulatory oversight.
A major focus of the guidance is the role of the Responsible Person (RP). The RP is responsible for maintaining oversight of the GDP quality system, managing documentation, overseeing recalls, approving suppliers and outsourced activities, and ensuring staff training and compliance activities are effectively implemented. The guidance emphasises that the RP must possess sufficient GDP knowledge and remain continuously contactable.
The document places strong emphasis on documentation control and SOP management. Companies are expected to keep all GDP records should remain traceable and retained for at least five years.
The guidance also outlines detailed expectations for handling deviations and implementing CAPA systems. The guidance additionally covers operational controls, including training, pest control, cleaning procedures, temperature monitoring, transportation, outsourced activities, recalls, and management of falsified medicines. These controls are intended to ensure that medicinal products maintain their quality and integrity throughout the distribution chain.
The HPRA also updated this guidance on 13 May 2026. The document explains how pharmaceutical companies and stakeholders can engage with the HPRA before submitting applications or implementing major GXP-related operational changes.
The document explains that “GXP” broadly includes activities related to GMP, GDP, GCP, GVP, active substance distribution, pharmacovigilance, clinical trials, cosmetics, controlled drugs, and related regulated activities. The overall objective of pre-submission advice is to help companies better understand regulatory expectations and improve compliance readiness before formal applications or inspections occur.
The guidance notes that pre-submission advice is especially important for companies planning new manufacturing or wholesale operations, facility expansions, technology transfers, or operational modifications. The guidance also explains that pharmaceutical companies planning GMP or GDP facilities may request regulatory review meetings before formal inspections.
Additional sections of the guidance discuss advice available for activities such as batch certification, procurement and supply operations, brokering of medicines, active substance importation and distribution, pharmacovigilance systems, advertising compliance, export certification, and controlled substance activities.
Guidance 3: Guide to Managing Changes to Registrations of Active Substance Manufacturers, Importers and Distributors
This updated guidance was published on 11 May 2026 and focuses on regulatory requirements introduced under the Falsified Medicines Directive (FMD) 2011/62/EU.
The guidance explains that manufacturers, importers, and distributors of active substances are required to maintain their registrations with the HPRA and appropriately manage any operational changes that could impact product quality or patient safety.
The document highlights the importance of formal change control and risk management processes whenever significant operational modifications occur. The guidance also requires immediate notification for changes involving company names, registered addresses, and significant manufacturing activities. Companies submitting notifications are expected to provide supporting documentation including chemistry overviews, process validation information, containment measures, equipment modifications, and cleaning validation data.
The document further explains that some changes may require GMP inspections before approval is granted, depending on the complexity and regulatory impact of the proposed modifications.
The guidance reinforces the importance of maintaining regulatory transparency and applying structured change management principles throughout active substance operations.
For pharmaceutical manufacturers, wholesalers, importers, distributors, and active substance operators, these updates highlight the growing expectation for structured compliance systems and risk-based operational oversight throughout the product lifecycle.
Comments